Philips signs off on CEO’s replacementImmunomedics has announced that Syncor International will distribute the radiopharmaceutical firm’s CEA-Scan colorectal cancer agent. The deal complements a distribution deal signed earlier this year
Philips signs off on CEOs replacement
Immunomedics has announced that Syncor International will distribute the radiopharmaceutical firms CEA-Scan colorectal cancer agent. The deal complements a distribution deal signed earlier this year with Bergen Brunswig (SCAN Special Report 6/98), which replaced a prior arrangement with Mallinckrodt.
Bergen Brunswig will provide nonradiolabeled CEA-Scan to Syncor, which will radiolabel the CEA-Scan with technetium at its 118 U.S. radiopharmacies, according to an Immunomedics spokesperson. Syncor, of Woodland Hills, CA, will then provide CEA-Scan to its customers in ready-to-use dosages. Syncor will also support Morris Plains, NJ-based Immunomedics with its own sales force.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.